Zobrazeno 1 - 10
of 22
pro vyhledávání: '"F. F. Cabanillas"'
Publikováno v:
Cancer. 84(1)
The histologic features of primary mediastinal non-Hodgkin's nonlymphoblastic lymphoma (NHL) are well described in the surgical pathology literature. However, the fine-needle aspiration (FNA) cytology of these lesions has not been characterized thoro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a205ef61505c96016b4977e4fb86f651
https://pubmed.ncbi.nlm.nih.gov/9500649
https://pubmed.ncbi.nlm.nih.gov/9500649
Publikováno v:
Cancer. 75(9)
Primary lymphomas of the uterus or cervix are so rare that treatment series of single institutions consist of very small numbers of patients, making standard treatment difficult to define. The outcome of patients treated with a combination of chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::578553a7a40376ed4424a9fe759ca746
https://pubmed.ncbi.nlm.nih.gov/7712450
https://pubmed.ncbi.nlm.nih.gov/7712450
Autor:
W S, Velasquez, P, McLaughlin, L M, Fuller, P K, Allen, S L, Tucker, F, Swan, M A, Rodriguez, F B, Hagemeister, F F, Cabanillas
Publikováno v:
Cancer. 73(9)
Numerous treatment strategies have been tried with the aim of improving results for patients with intermediate-grade lymphomas (IGL) over those achieved with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-Bleo), and numer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2de448105076ab284072e0d1127363c2
https://pubmed.ncbi.nlm.nih.gov/7513251
https://pubmed.ncbi.nlm.nih.gov/7513251
Autor:
Barry W. Brown, S. O. Zimmerman, Lillian M. Fuller, Pamela K. Allen, M. F. Munsell, William S. Velasquez, P. McLaughlin, F. Swan, Maria A Rodriguez, Fredrick B. Hagemeister, F. F. Cabanillas
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 4(2)
BACKGROUND Advances in radiotherapy and chemotherapy have gradually increased cure rates for patients with Hodgkin's disease. With improved long-term survivals, increases in observed second malignancies over those of the general population have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0f223952901c89a9cc5a61e94445dd8
https://pubmed.ncbi.nlm.nih.gov/8448080
https://pubmed.ncbi.nlm.nih.gov/8448080
Autor:
K V, Rolston, P, Berkey, G P, Bodey, E J, Anaissie, N M, Khardori, J H, Joshi, M J, Keating, F A, Holmes, F F, Cabanillas, L, Elting
Publikováno v:
Archives of internal medicine. 152(2)
Neutropenic patients with cancer are traditionally treated with empiric antibiotic combinations when they become febrile. The availability of broad-spectrum antibiotics such as ceftazidime and imipenem has made it possible to initiate therapy with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e8236ac0742b46fdf0bda1e17bc6b887
https://pubmed.ncbi.nlm.nih.gov/1739355
https://pubmed.ncbi.nlm.nih.gov/1739355
Autor:
N, Sneige, R H, Dekmezian, R L, Katz, T V, Fanning, J L, Lukeman, N F, Ordoñez, F F, Cabanillas
Publikováno v:
Acta cytologica. 34(3)
A total of 220 fine needle aspiration (FNA) specimens from 212 patients with clinically suspected or previously histologically confirmed lymphoma were evaluated by cytology in conjunction with immunophenotyping analysis of the aspirate; the results w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f7c4f3628dd12d1c7e75a4d4226cb5cb
https://pubmed.ncbi.nlm.nih.gov/2111624
https://pubmed.ncbi.nlm.nih.gov/2111624
Autor:
James L. Murray, Daniel J. Macey, P. W. McLaughlin, Donald A. Podoloff, R. E. Wendt, W. F. Broussard, F. F. Cabanillas
Publikováno v:
CLINICAL NUCLEAR MEDICINE. 22:200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d7285379bc4afb8bd748a29381f2340
https://doi.org/10.1097/00003072-199703000-00025
https://doi.org/10.1097/00003072-199703000-00025
Publikováno v:
Ecological Restoration; Sep2024, Vol. 42 Issue 3, p220-237, 18p
Publikováno v:
Cancer treatment reports. 66(5)
Pentamethylmelamine, an analog of hexamethylmelamine developed for iv use, was administered to 42 patients in a phase I clinical trial. The dose ranged from 0.080 to 2.50 g/m2/day x 5 and was repeated approximately every 3 weeks. The dose-limiting to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::04e6617f1fb7997b0217f61783df5fed
https://pubmed.ncbi.nlm.nih.gov/6805950
https://pubmed.ncbi.nlm.nih.gov/6805950
Publikováno v:
Case Reports in Hematology. 8/11/2016, p1-4. 4p.